Aripiprazole treatment analysis of 50 cases of schizophrenia.docVIP

 PAGE \* MERGEFORMAT 7 Aripiprazole treatment analysis of 50 cases of schizophrenia [Paper Keywords] Aripiprazole, adverse reactions, efficacy [Abstract] Objective: To observe and explore the new antipsychotic aripiprazole adverse reactions and efficacy. Methods: 50 inpatients with schizophrenia treated with aripiprazole treatment, the observed adverse reactions and efficacy, and use side effects scale (TESS before treatment and after treatment were assessed at the end of 1,3,6, with the overall clinical rating scale (CGL 3 efficacy evaluation for results: 50 cases, 24 cases of adverse reactions, the incidence of to 48.00% Conclusion: aripiprazole adverse reactions and light, has a good safety, tolerability and treatment compliance, the first month of treatment the worst, with the extension of treatment time, drug efficiency , significantly increased efficiency. individual patients with mental symptoms, should be promptly discontinued. Aripiprazole is a quinolinone derivative, is the latest generation of atypical antipsychotic drugs, known as a neurotransmitter dopamine stabilizers [1-3] It was in November 2002 by the FDA approved in the U.S. market, made in November 2004, the beginning of aripiprazole to market our hospital from the end of 2005 with aripiprazole, the drug will now appear in the clinical application and preliminary efficacy of adverse reactions reported are as follows: 1 Materials and Methods 1.1 General Information The group of 50 patients in our hospital on December 6, 2007 hospitalized patients with chronic schizophrenia, in line with lt;lt;Chinese Classification and Diagnostic Criteria of Mental Disordersgt;gt; Version 3 (CCMD-3 diagnostic criteria: have used a variety of anti-psychotic drugs were no significant effects, excluding patients with severe somatic diseases, among which 34 males and 16 females, aged 35 to 65 years (mean 40 + -9.38 years, duration of one year, an average of 3 to 5 years. 1.2 Methods